Fig. 6

Analysis of Arl8b expression in human brain and CSF samples. a Detection of Arl8b protein aggregates in postmortem brain homogenates of 10 AD patients (1 to 10, black lettering) and 10 age-matched controls (11 to 20, red lettering) using a native MFA. Triplicates per sample were filtered. For immunoblotting, an anti-Arl8a/b antibody was used. b Quantification of protein aggregates retained on filter membrane in a was performed using Aida image analysis software. Data are expressed as mean ± SD. The statistical significance was assessed with an unpaired, two-tailed t-test (****, p < 0.0001). c Determination of Arl8b concentrations in CSF samples of 38 AD patients and 44 control individuals (Ctrl) using an ELISA. Data represent mean ± SD. Statistical significance was determined using an unpaired, two-tailed t-test (***, p = 0.0002). d Arl8b ELISA using CSF samples of 10 Huntington’s disease (HD) patients, 10 controls (Ctrl HD), 3 AD patients, and 3 controls (Ctrl AD). Data are mean ± SD. Statistical significance was evaluated using an unpaired, two-tailed t-test between HD and Ctrl HD, and AD and Ctrl AD groups (**, p = 0.0041). e ROC analysis of Arl8b levels derived from both AD patients and control individuals using GraphPad Prism software. The area under the curve (AUC) is 0.73 with a p-value of 0.0003